Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update